ClinicalTrials.Veeva

Menu

Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy Subjects

Bristol-Myers Squibb (BMS) logo

Bristol-Myers Squibb (BMS)

Status and phase

Completed
Phase 1

Conditions

HIV

Treatments

Drug: Atazanavir (current formulation)
Drug: Atazanavir (POU2)
Drug: Atazanavir, powder for oral use 1 (POU1)

Study type

Interventional

Funder types

Industry

Identifiers

NCT01404572
AI424-466

Details and patient eligibility

About

The purpose of this study is to compare the sweetness of 2 new atazanavir powder for oral use (POU) formulations to the current atazanavir POU in healthy participants and to select 1 atazanavir POU that has the sweetness most similar to the current atazanavir POU.

Full description

This study is a taste assessment study designed to select a new atazanavir powder for oral use (POU) formulation that is similar in sweetness to the current POU formulation. Participants were to taste and then spit out the POU formulations, without swallowing them. Study Classification: Other. This is a taste study

Enrollment

12 patients

Sex

All

Ages

18 to 49 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Key inclusion criteria:

  • Healthy men and women, ages 18 to 49, inclusive
  • Nonsmokers
  • Women not pregnant or breastfeeding
  • Participants who could match solutions of the same sweetness and provide consistent sweetness scores during the taste screening

Key exclusion criteria:

  • Any significant acute or chronic medical illness
  • Any acute or chronic condition that may have altered taste sensory perception
  • Any major surgery or trauma within 4 weeks of Day 1
  • Blood transfusion within 4 weeks of study participation
  • Recent (within 6 months of Day 1) drug or alcohol abuse as defined in the Diagnostic and Statistical Manual, 4th edition, Diagnostic Criteria for Drug and Alcohol Abuse
  • Positive urine drug screen
  • Positive urine screen for cotinine
  • Positive hepatitis C antibody, hepatitis B surface antigen, or human immunodeficiency virus antibodies
  • Clinically significant elevations in results of liver function tests above normal range

Trial design

12 participants in 3 patient groups

Atazanavir + 10% aspartame
Active Comparator group
Treatment:
Drug: Atazanavir (current formulation)
Atazanavir + 4.2% aspartame
Active Comparator group
Treatment:
Drug: Atazanavir, powder for oral use 1 (POU1)
Atazanavir + 4.2% aspartame and sucralose
Active Comparator group
Treatment:
Drug: Atazanavir (POU2)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems